Mettler Toledo
MTD · What the business does, what can go wrong, and how options sellers approach it
What it does
Mettler-Toledo makes precision instruments that measure things. Its best-known products are laboratory balances and scales, but it also sells pipettes, pH meters, titrators, thermal analysis equipment, and product inspection systems such as metal detectors and X-ray analyzers.
Customers include pharmaceutical and biotech labs, industrial manufacturers, and food producers and retailers. The company sells worldwide.
How it makes money
It earns revenue in two main ways: selling instruments and software, and providing service. Service includes calibration, repair, maintenance, and compliance support. Many customers work in regulated settings, so they need their equipment checked and certified on a recurring basis.
That service work tends to be steadier than new equipment sales, which depend more on customer spending plans.
Why investors own it
Investors often see MTD as a high-quality industrial technology business. Its instruments are small relative to a customer's total costs but critical to accuracy, so customers tend to value reliability and brand over price alone. The installed base creates repeat demand for service and consumables.
The company also has a long record of focusing on pricing discipline, cost control, and share repurchases, and its exposure to both life sciences and industry diversifies its end markets.
What can go wrong
- Customers may delay equipment purchases when budgets tighten, especially in pharma, biotech, and manufacturing.
- Demand in China or other major regions can swing with the local economy and policy.
- Currency moves can affect reported results, since sales are global.
- Competitors, including large life science tool makers, could pressure pricing or share.
- If the stock trades at a premium valuation, it can be sensitive to any disappointment.
What to watch
- Organic sales growth by region and by end market
- Service revenue trends
- Operating margin and pricing versus cost inflation
- Commentary on lab and pharma spending
- Currency effects on results
- Pace of share repurchases
Options income angle
Options on MTD are generally available across a range of expirations, but liquidity is thinner than for mega-cap stocks. Bid-ask spreads can be wide, especially on strikes far from the current price, so check open interest and volume before trading.
Implied volatility tends to rise ahead of quarterly earnings and when investors worry about life science or industrial demand. It often eases after results.
One caution for premium sellers: when the share price is high, one contract controls a large dollar amount of stock. A sharp earnings gap can lead to a large loss on a short put or a capped upside on a covered call.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 6, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Mettler-Toledo, which makes precision weighing and measuring instruments, grew sales in 2025 while tariffs squeezed its margins. China is a large share of its profit and production, and it carries about $2.2 billion of debt. The company is funding large share repurchases from cash flow and borrowings.
How the business did
- Net sales were $4.0 billion for 2025, compared to $3.9 billion in 2024. That is up 4% in U.S. dollars and 3% in local currencies, which strips out exchange rate effects. Service revenue rose 8% in U.S. dollars, ahead of the 3% rise in product sales.
- Gross profit as a percentage of net sales was 59.4% for 2025, compared to 60.1% for 2024. Management cited tariff costs, lower volume after the prior year's shipping-delay recovery, and unfavorable mix, partly offset by pricing. Selling, general, and administrative expenses rose to 24.8% of net sales from 24.2%.
- Segment profit rose 14% in Other Operations and 10% in Western European Operations. It fell 5% in U.S. Operations on higher tariff costs. Chinese Operations segment profit decreased $0.9 million.
- Cash provided by operating activities was $955.8 million, compared to $968.3 million in 2024. The company spent $800 million on share repurchases.
- Management estimated tariff costs of approximately $50 million before mitigation. The 17% tax rate included a non-cash discrete tax benefit of $13.7 million from a tax audit settlement.
Risks specific to this company
- China concentration: Chinese operations accounted for 16% of sales to external customers, 29% of total segment profit, and approximately 29% of global production. Demand there fell sharply starting in the second half of 2023, and approval is needed to convert and repatriate earnings.
- Tariffs: Tariffs raised costs and hurt gross margin. The company says its mitigation steps, including price increases, may not cover future tariffs, and higher prices could reduce demand.
- Customer industries: Sales depend heavily on pharma/biopharmaceutical, food manufacturing, and chemical customers, which have cut back on equipment spending. Recent cuts in U.S. research funding have also hit government and academic buyers.
- Swiss franc exposure: The company makes products in Switzerland but sells more in euros. A 1% strengthening of the Swiss franc against the euro would reduce earnings before tax by approximately $2.8 million to $3.1 million annually.
- Debt: Total indebtedness was approximately $2.2 billion, net of cash of $66.9 million. Borrowings under the $1.35 billion credit facility were $813.7 million. Breaching loan covenants could let lenders demand immediate repayment.
- Single-site production: Many products are made at single locations with limited alternates, and some inputs come from a single supplier. A disruption could cost sales, and customers might not return.
What management is watching
- Management plans to spend $825 million to $875 million on share repurchases in 2026, subject to business and economic conditions. Capital expenditures are expected to approximate $130 million.
- It expects to benefit from automation and digitalization trends, customer replacement cycles, and on/near-shoring investment (moving production closer to home markets). It says timing is unclear and pharma, food, and chemical markets remain challenged.
- It has implemented actions to fully offset the effect of the current incremental tariffs in 2026, and notes that further U.S. tariff changes could hurt results.
- Growth and margin programs include Spinnaker (sales and marketing), SternDrive (supply chain and operations efficiency), and Blue Ocean (a standardized global systems platform). Research and development runs at approximately 5% of net sales.
- Management points to local currency sales growth and expects interest payments of approximately $71.0 million during 2026.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 6, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Mettler-Toledo grew third-quarter net sales 6% in U.S. dollars and improved its gross margin to 59.8% from 59.2%, with net earnings of $245,953 thousand against $217,493 thousand a year earlier. Nine-month results were also lifted by a one-time U.S. tariff refund, which management separates from underlying performance. Asia, and China in particular, was the strongest region.
How the business did
- Quarter: Local currency sales also rose 6%. Gross margin gained on favorable price realization, lower tariff costs and higher volume, partly offset by higher material and transportation costs. Selling, general and administrative expenses rose 8%, reflecting sales and marketing investments and higher variable compensation.
- Nine months and the tariff refund: Sales rose 6% in U.S. dollars. Cost of sales included a one-time $52 million benefit from refunds of tariffs struck down by the U.S. Supreme Court, partly offset by $28 million of related customer refunds that reduced net sales. Gross margin was 60.6%, or 59.3% excluding both refunds. Net earnings were $648,306 thousand versus $583,428 thousand.
- Where growth came from: In the quarter, Asia/Rest of World sales rose 14% in local currencies, including 13% in China. The Chinese Operations segment profit was $109,683 thousand versus $94,256 thousand. U.S. Operations external sales rose 1% but were flat on an organic basis (excluding acquisitions and the one-time refunds), with project activity in transportation and logistics and food retail down significantly. Food retailing sales fell 1% in U.S. dollars.
- Cash and capital return: Operating cash flow for the nine months was $758.8 million versus $730.2 million, including a net $49.6 million tariff refund benefit. The company spent $638.7 million on share repurchases and has $3.0 billion of authorization remaining. Capital expenditures were $72.3 million.
What management is watching
- Tariffs: New Section 301 tariffs took effect on July 23, 2026, at 12.5% on imports from Switzerland and China and 10% on imports from the European Union, the United Kingdom and non-USMCA Mexico. The U.S. government has discussed further tariffs and a possible end to USMCA treatment for Mexico. The company expects to pay more customer tariff refunds in the fourth quarter, after distributing $3 million in the third.
- Demand and the Iran War: Management says market conditions improved during 2026 and credits its sales programs, its products and digital tools. It flags uncertainty from the Iran War and trade disputes, including higher energy and transportation costs and inflation, although it has no significant direct Middle East exposure.
- Pension: In October 2026 the company bought an insurance contract covering substantially all U.S. pension plan assets (a "buy-in"). It expects to terminate the plan in 2027, which would trigger a one-time non-cash charge. The related deferred actuarial loss was approximately $28 million at quarter end.
- Currency: A 1% strengthening of the Swiss franc against the euro would reduce annual earnings before tax by approximately $2.6 million to $2.9 million. Management points investors to local currency and organic growth figures, which are non-GAAP measures.
Follow MTD in Kortex
The Kortex app shows MTD's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.